← All causality assessments
Causality assessment · Causality: well established

Phenytoin and Stevens–Johnson syndrome / TEN: is the FAERS signal real?

n=771 co-reports · PRR 36.2 · ROR 37.6
A written Bradford Hill assessment of one drug–event pair. The grade is a judgement about the signal, not a statement that this drug causes this event in any one person; FAERS counts are reports, not rates.
Causality: well established

Phenytoin ↔ Stevens–Johnson syndrome / TEN

n=771 co-reports · PRR 36.2 · ROR 37.6

Phenytoin, an older antiepileptic also used in some cardiac and neurosurgical settings, is another leading cause of Stevens–Johnson syndrome and toxic epidermal necrolysis, with the same aromatic-antiepileptic, HLA-linked pattern seen with carbamazepine. The reaction usually appears within the first weeks of therapy and requires immediate withdrawal. The 771 co-reports (PRR 36.2) reflect both the severity of the reaction and the drug's continued use worldwide.

Regulatory basis: phenytoin prescribing information (SJS/TEN warning; HLA-B*15:02 caution). Established phenytoin-HLA pharmacogenomics.

Bradford Hill viewpointStatusNote
Temporality (necessary)metSkin reaction appears early in therapy and is managed by immediate withdrawal
StrengthmetPRR 36 on a large co-report count
ConsistencymetReproduced across populations and linked to HLA-B*15:02
SpecificitypartialShared with other aromatic antiepileptics, a class pattern
Biological gradientpartialLinked more to genetic risk than to a simple dose gradient
PlausibilitymetImmune-mediated keratinocyte death, often HLA-restricted, is the mechanism
CoherencemetCoheres with the labelled warnings and genetic-screening advice
ExperimentpartialDechallenge (immediate withdrawal) is essential and can be life-saving; no randomized trial
AnalogymetAnalogous to SJS/TEN from carbamazepine, lamotrigine, and allopurinol

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for phenytoin captured SJS/TEN; it is a rare, severe idiosyncratic reaction identified through case series and pharmacogenetics rather than a trial AE table.